Oral Nanoparticles Exhibit Specific High-Efficiency Intestinal Uptake and Lymphatic Transport
- ACS Nano. 2018 Sep 25;12(9):8893-8900. doi: 10.1021/acsnano.8b04315.
- 1. Department of Pharmaceutics and Pharmaceutical Chemistry , University of Utah , Salt Lake City , Utah 84112 , United States.
- 2. Fuji Research Laboratories, Pharmaceutical Division , Kowa Co. Ltd. , 332-1 Ohnoshinden , Fuji , Shizuoka 417-8650 , Japan.
- 3. School of Pharmacy , Sungkyunkwan University , Suwon , Gyeonggi-do 16419 , Republic of Korea.
Herein, we describe a simple and promising nanoparticle oral delivery phenomenon and propose pathways for oral nanoparticle absorption from the gastrointestinal tract (GIT), combining apical sodium-dependent bile acid transporter-mediated cellular uptake and chylomicron transport pathways. This strategy is proven to employ bile-acid-conjugated, solid fluorescent probe nanoparticles (100 nm diameter) to exclude any potential artifacts and instability issues in observing transport pathways and measuring oral bioavailability. The results of the in vitro studies showed that there is no interference from bile acid and no simultaneous uptake of nanoparticles and dextran. The probe nanoparticle exhibited a significantly enhanced average oral bioavailability (47%) with sustained absorption in rats. Particle-size- and dose-dependent oral bioavailability was observed for oral nanoparticle dosing up to 20 mg/kg. The probe nanoparticles appear to be transported to systemic circulation via the gut lymphatic system. Thus, we propose a pathway for oral nanoparticle absorption from the GIT, combining apical bile acid transporter-mediated cellular uptake and chylomicron transport pathways.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Others